Texas Instruments' Q1 beat and full-year guidance set up a second-half revenue trajectory that pushes run-rate EPS above $9—a normalization path the market started pricing April 30.
Texas Instruments' Q1 beat and full-year guidance set up a second-half revenue trajectory that pushes run-rate EPS above $9—a normalization path the market started pricing April 30.
In recent years, we have discovered that all mammals have a endocannabinoid system. Just like humans, their bodies have a vast network of neurotransmitters...